Billiontoone (NASDAQ:BLLN) Insider Thomas Lynch Sells 20,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Thomas Lynch sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $99.99, for a total transaction of $1,999,800.00. Following the completion of the transaction, the insider owned 700 shares in the company, valued at $69,993. This trade represents a 96.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

NASDAQ:BLLN opened at $98.51 on Friday. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. The firm’s 50-day simple moving average is $112.07 and its 200 day simple moving average is $95.79. The firm has a market cap of $4.65 billion and a price-to-earnings ratio of 140.73.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The firm had revenue of $109.45 million during the quarter. As a group, sell-side analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Rossby Financial LCC acquired a new stake in shares of Billiontoone in the 4th quarter valued at $25,000. Integrated Wealth Concepts LLC acquired a new position in shares of Billiontoone during the 2nd quarter worth $29,000. MCF Advisors LLC lifted its position in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after buying an additional 344 shares during the last quarter. Wells Fargo & Company MN acquired a new stake in Billiontoone in the fourth quarter valued at about $76,000. Finally, Smartleaf Asset Management LLC acquired a new stake in Billiontoone in the fourth quarter valued at about $80,000.

Analyst Upgrades and Downgrades

BLLN has been the topic of a number of recent research reports. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Guggenheim started coverage on Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 target price for the company. Canaccord Genuity Group began coverage on Billiontoone in a report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Finally, BTIG Research dropped their price target on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Billiontoone presently has a consensus rating of “Hold” and a consensus target price of $125.88.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.